Larimar Corp (LRMR) - Long-Term Debt to Capital Coefficient

The following Larimar Therapeutics (LRMR) quotes demonstrate the dynamics of a company developing an innovative method to combat a rare nervous system disorder. A lack of alternatives allows the firm to maintain significant pricing power, with the indicator standing at 0.03. Business growth relies on Friedreich's ataxia therapy test results and patent protection. Environmental policy is limited to the safe disposal of chemicals within laboratories.

Larimar Therapeutics (LRMR) is developing a diversified portfolio of drugs for the treatment of rare genetic pathologies, which requires significant long-term financing. This long-term debt-to-equity ratio measures the share of borrowed funds with a maturity of over one year within the asset structure, allowing for an assessment of the biotech's financial stability. A low ratio confirms the company's autonomy, while an increase signals a growing credit burden.